Condition: Breast Cancer · Sponsor: Daiichi Sankyo
This study will compare DS 8201a to standard treatment. Participants must have HER2 breast cancer that has been treated before. Their cancer: * cannot be removed by an operation * has spread to other parts of the body
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Ironwood Cancer Research Centers | Chandler, Arizona, United States | — |
| UCLA Hematology Oncology - Main Site | Los Angeles, California, United States | — |
| Pacific Cancer Care | Monterey, California, United States | — |
| Sharp Memorial Hospital | San Diego, California, United States | — |
| Innovative Clinical Research Institute | Whittier, California, United States | — |
| Smilow Cancer Hospital at Yale New Haven | New Haven, Connecticut, United States | — |
| Washington Cancer Institute | Washington D.C., District of Columbia, United States | — |
| Florida Cancer Specialists-Broadway | Fort Myers, Florida, United States | — |
| Piedmont Cancer Institute, PC | Atlanta, Georgia, United States | — |
| Kapiolani Medical Center for Women and Children/Univ of HI | Honolulu, Hawaii, United States | — |
| Loyola University Health System | Maywood, Illinois, United States | — |
| Community Hospital | Munster, Indiana, United States | — |
+ 215 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.